Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (NQ:LSE)

4.560 -0.020 (-0.44%)

Streaming Delayed Price Updated: 3:59 PM EST, Jan 30, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,171
Open	4.400
Bid (Size)	4.250 (900)
Ask (Size)	5.100 (500)
Prev. Close	4.580
Today's Range	4.400 - 4.560
52wk Range	4.030 - 14.99
Shares Outstanding	17,025,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Interim Results for the six months ended 31 October 2025

January 29, 2026

From Scancell Holdings Plc

Via GlobeNewswire

Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma

January 26, 2026

From Scancell Holdings Plc

Via GlobeNewswire

Performance

YTD	+6.8%	+6.8%
1 Month	+4.3%	+4.3%
3 Month	-14.0%	-14.0%
6 Month	-17.8%	-17.8%
1 Year	-41.7%	-41.7%

More News

Leishen Energy Holding Co., Ltd. Announces Receipt of Nasdaq Notice Regarding Annual Meeting Requirement

January 23, 2026

From Leishen Energy Holding Co., Ltd.

Via GlobeNewswire

Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)

January 21, 2026

From AVACTA GROUP PLC

Via GlobeNewswire

Avacta Announces Year-end Trading Update

January 20, 2026

From AVACTA GROUP PLC

Via GlobeNewswire

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

January 13, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

January 06, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

January 04, 2026

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

December 30, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

December 29, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

Caledonia Mining Corporation Plc: Director/PDMR Shareholding Notification

December 23, 2025

From Caledonia Mining Corporation Plc

Via GlobeNewswire

Caledonia Mining Corporation Plc: Zimbabwe government amends proposed changes to the royalty and tax regimes

December 19, 2025

From Caledonia Mining Corporation Plc

Via GlobeNewswire

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers

December 17, 2025

From AVACTA GROUP PLC

Via GlobeNewswire

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

December 16, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

Caledonia Mining Corporation Plc: Utilisation of the block admission in respect of ATM Sales Agreement

December 16, 2025

From Caledonia Mining Corporation Plc

Via GlobeNewswire

Caledonia Mining Corporation Plc: Notification of relevant change to significant shareholder

December 10, 2025

From Caledonia Mining Corporation Plc

Via GlobeNewswire

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma

December 09, 2025

From Scancell Holdings Plc

Via GlobeNewswire

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China

December 07, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

Empire to Present at the Precious Metals & Critical Minerals Virtual Investor Conference

December 01, 2025

From Virtual Investor Conferences; Empire Metals Limited

Via GlobeNewswire

Caledonia Mining Corporation Plc: Proposed Changes to Royalty and Tax Regimes in Zimbabwe

December 01, 2025

From Caledonia Mining Corporation Plc

Via GlobeNewswire

Caledonia Mining Corporation Plc: Reminder of Remote Presentation on Publication of Feasibility Study for Bilboes Gold Project in Zimbabwe

November 28, 2025

From Caledonia Mining Corporation Plc

Via GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

November 26, 2025

From HUTCHMED (China) Limited

Via GlobeNewswire

Caledonia Mining Corporation Plc: Publication and Highlights of the Feasibility Study for Bilboes Gold Project

November 25, 2025

From Caledonia Mining Corporation Plc

Via GlobeNewswire

UPDATE - Leishen Energy(LSE) Makes a Strong Debut at ADIPEC Abu Dhabi, Embarking on a New Chapter of Strategic Expansion in the Middle East and International Markets

November 13, 2025

From Leishen Energy Holding Co., Ltd.

Via GlobeNewswire

Caledonia approves quarterly dividend

November 10, 2025

From Caledonia Mining Corporation Plc

Via GlobeNewswire

Frequently Asked Questions

Is Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares publicly traded?

Yes, Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is publicly traded.

What exchange does Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares trade on?

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?

The ticker symbol for Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is LSE on the Nasdaq Stock Market

What is the current price of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?

The current price of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is 4.560

When was Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares last traded?

The last trade of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares was at 01/30/26 03:59 PM ET

What is the market capitalization of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares?

The market capitalization of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares is 77.63M

How many shares of Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares are outstanding?

Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares has 78M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.